NRx Pharmaceuticals (NASDAQ:NRXP) Receives “Buy” Rating from BTIG Research

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reiterated by equities research analysts at BTIG Research in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $25.00 target price on the stock.

NRXP has been the topic of several other research reports. Zacks Research upgraded shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. D. Boral Capital restated a “buy” rating and set a $34.00 price target on shares of NRx Pharmaceuticals in a research note on Monday, March 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NRx Pharmaceuticals in a report on Monday, December 29th. HC Wainwright raised their target price on NRx Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Finally, Ascendiant Capital Markets restated a “buy” rating and set a $48.00 target price (up from $47.00) on shares of NRx Pharmaceuticals in a research report on Friday, January 2nd. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

NRx Pharmaceuticals Stock Up 13.5%

Shares of NASDAQ:NRXP traded up $0.24 during trading on Tuesday, reaching $2.01. 743,030 shares of the company traded hands, compared to its average volume of 1,048,546. The firm has a fifty day simple moving average of $1.94 and a 200 day simple moving average of $2.44. NRx Pharmaceuticals has a 1-year low of $1.58 and a 1-year high of $3.84. The firm has a market cap of $64.03 million, a P/E ratio of -0.86 and a beta of 1.97.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings results on Monday, March 23rd. The company reported $0.19 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.28. The company had revenue of $0.98 million during the quarter, compared to analyst estimates of $7.53 million. As a group, research analysts anticipate that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Hedge Funds Weigh In On NRx Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. Anson Funds Management LP grew its stake in NRx Pharmaceuticals by 50.3% in the fourth quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock valued at $8,249,000 after acquiring an additional 1,018,853 shares during the period. Vanguard Group Inc. raised its position in shares of NRx Pharmaceuticals by 18.3% during the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock worth $1,765,000 after purchasing an additional 82,781 shares during the period. Commonwealth Equity Services LLC bought a new position in shares of NRx Pharmaceuticals during the 4th quarter valued at about $994,000. AdvisorShares Investments LLC grew its position in shares of NRx Pharmaceuticals by 29.7% in the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock valued at $1,129,000 after purchasing an additional 78,339 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of NRx Pharmaceuticals by 17.8% in the 4th quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock valued at $593,000 after purchasing an additional 33,004 shares during the period. Institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.